News and Analysis | Published:

Alnylam prepares to land first RNAi drug approval

Nature Reviews Drug Discovery volume 17, pages 156157 (2018) | Download Citation

With Alnylam's rare disease drug candidate patisiran nearing the regulatory finish line, the RNA interference community is now turning its attention to next-generation delivery technology to solidify the future of the emerging modality.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

About this article

Publication history




  1. Search for Chris Morrison in:

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing